SH3BP1 and chronic myelogenous leukemia, BCR-ABL1 positive: Our results suggest that the pharmacologic targeting of the Cobll1/PACSIN2/SH3BP1 axis can be a novel approach to overcome TKI resistance and disease progression in CML.